Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype.
暂无分享,去创建一个
Li Wang | Luca Malcovati | Mario Cazzola | David Oscier | M. Cazzola | C. Langford | D. Oscier | J. Boultwood | L. Malcovati | A. Pellagatti | A. Giagounidis | M. Porta | S. Killick | J. Wainscoat | C. Aul | Andrea Pellagatti | Jacqueline Boultwood | James S Wainscoat | Cordelia F Langford | Carrie Fidler | Sally Killick | Li Wang | C. Fidler | Carlo Aul | Aristoteles A N Giagounidis | Matteo G Della Porta | Lisa J Campbell | L. Campbell | M. D. Porta
[1] P. Vyas,et al. Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome. , 2005, Blood.
[2] M. L. Beau,et al. The cytogenetics of myelodysplastic syndromes. , 2001, Best practice & research. Clinical haematology.
[3] S. Kajigaya,et al. Gene expression profiling in CD34 cells to identify differences between aplastic anemia patients and healthy volunteers. , 2004, Blood.
[4] D. Caput,et al. Expression Cloning of an Interferon-inducible 17-kDa Membrane Protein Implicated in the Control of Cell Growth (*) , 1995, The Journal of Biological Chemistry.
[5] J. Boultwood,et al. The 5q-syndrome. , 1994, Blood.
[6] L. Larue,et al. The WNT/Beta-catenin pathway in melanoma. , 2006, Frontiers in bioscience : a journal and virtual library.
[7] H Phillip Koeffler,et al. Myelodysplastic Bone Marrow Cells from Normal and + Characterization of Gene Expression of Cd34 , 2002 .
[8] T. Pollard,et al. Crystal Structure of Arp2/3 Complex , 2001, Science.
[9] R. Tibshirani,et al. Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[10] G. Tricot,et al. The 5q-anomaly. , 1985, Cancer genetics and cytogenetics.
[11] S. E. Jacobsen,et al. IFN-γ Negatively Modulates Self-Renewal of Repopulating Human Hemopoietic Stem Cells1 , 2005, The Journal of Immunology.
[12] P. Fenaux. Chromosome and Molecular Abnormalities in Myelodysplastic Syndromes , 2001, International journal of hematology.
[13] A. Verma,et al. Cytokine targets in the treatment of myelodysplastic syndromes. , 2005, Current hematology reports.
[14] L. Rimsza,et al. Efficacy of lenalidomide in myelodysplastic syndromes. , 2005, The New England journal of medicine.
[15] H. Preisler,et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. , 1995, Blood.
[16] E. Schuuring,et al. Identification and cloning of two overexpressed genes, U21B31/PRAD1 and EMS1, within the amplified chromosome 11q13 region in human carcinomas. , 1992, Oncogene.
[17] J U Gutterman,et al. Cytokine therapeutics: lessons from interferon alpha. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[18] B. Zhivotovsky,et al. Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors. , 2003, Blood.
[19] D. Helfman,et al. Cytoskeletal changes in cell transformation and tumorigenesis. , 2001, Current opinion in genetics & development.
[20] R. Hoffman,et al. Hematology: Basic Principles and Practice , 1995 .
[21] C. Dai,et al. Stem cell factor increases the expression of FLIP that inhibits IFNgamma -induced apoptosis in human erythroid progenitor cells. , 2003, Blood.
[22] M. Cazzola,et al. Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia. , 2003, Blood.
[23] T. Naoe,et al. Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. , 2004, Blood.
[24] Y. Yamashita,et al. Identification of myelodysplastic syndrome-specific genes by DNA microarray analysis with purified hematopoietic stem cell fraction. , 2001, Blood.
[25] P. Tsoplou,et al. Apoptosis in patients with myelodysplastic syndromes: differential involvement of marrow cells in ‘good’ versus ‘poor’ prognosis patients and correlation with apoptosis-related genes , 1999, Leukemia.
[26] C. Schoch,et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31 , 2004, Leukemia.
[27] T Hamblin,et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.
[28] G Flandrin,et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] M. Hubank. Gene expression profiling and its application in studies of haematological malignancy , 2004, British journal of haematology.
[30] D. Steensma,et al. Genetic testing in the myelodysplastic syndromes: molecular insights into hematologic diversity. , 2005, Mayo Clinic proceedings.
[31] C. Langford,et al. Identification of acquired somatic mutations in the gene encoding chromatin-remodeling factor ATRX in the α-thalassemia myelodysplasia syndrome (ATMDS) , 2003, Nature Genetics.
[32] R. Eils,et al. Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[33] S. Kajigaya,et al. Interferon-gamma-induced gene expression in CD34 cells: identification of pathologic cytokine-specific signature profiles. , 2006, Blood.
[34] R. Abramson,et al. Detection of specific polymerase chain reaction product by utilizing the 5'----3' exonuclease activity of Thermus aquaticus DNA polymerase. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[35] R. Tibshirani,et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. , 2004, The New England journal of medicine.
[36] T. A. Lister,et al. Genome‐wide analysis of acute myeloid leukemia with normal karyotype reveals a unique pattern of homeobox gene expression distinct from those with translocation‐mediated fusion events , 2003, Genes, chromosomes & cancer.
[37] P. Ji,et al. Alterations of lymphoid enhancer factor-1 isoform expression in solid tumors and acute leukemias. , 2005, Acta biochimica et biophysica Sinica.
[38] Rafael A Irizarry,et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.
[39] N. Cross,et al. Low expression of the putative tumour suppressor gene gravin in chronic myeloid leukaemia, myelodysplastic syndromes and acute myeloid leukaemia , 2004, British journal of haematology.
[40] C. Langford,et al. Gene expression profiling in polycythemia vera using cDNA microarray technology. , 2003, Cancer research.
[41] K. Livak,et al. Real time quantitative PCR. , 1996, Genome research.
[42] D. Galton. The myelodysplastic syndromes. , 1987, Clinical and laboratory haematology.
[43] P. Greenberg,et al. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells , 1996 .
[44] Bengt Fadeel,et al. Apoptosis in refractory anaemia with ringed sideroblasts is initiated at the stem cell level and associated with increased activation of caspases , 2001, British journal of haematology.
[45] H. Gralnick,et al. Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.
[46] C. Langford,et al. Gene expression profiling in the myelodysplastic syndromes using cDNA microarray technology , 2004, British journal of haematology.
[47] Y Yoshida,et al. Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. , 1998, Haematologica.
[48] E. Sausville,et al. dlk, a putative mammalian homeotic gene differentially expressed in small cell lung carcinoma and neuroendocrine tumor cell line. , 1993, The Journal of biological chemistry.
[49] Thomas D. Schmittgen,et al. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.
[50] K. Hirokawa,et al. Overexpression of tumor necrosis factor (TNF)-α and interferon (IFN)-γ by bone marrow cells from patients with myelodysplastic syndromes , 1997, Leukemia.
[51] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[52] W. Hiddemann,et al. Genomic gains and losses influence expression levels of genes located within the affected regions: a study on acute myeloid leukemias with trisomy 8, 11, or 13, monosomy 7, or deletion 5q , 2005, Leukemia.
[53] J. D. Vos,et al. Fas/Apo-1(CD95) expression and apoptosis in patients with myelodysplastic syndromes , 1997, Leukemia.